Preclinical News and Research

RSS

Onconova uses BioClinica EDC, data management services to support clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced that Onconova Therapeutics, Inc. has extended agreements using BioClinica Express electronic data capture (EDC) and data management services to support their clinical trials world-wide.

From Clario 1 Dec 2011

arGEN-X closes EUR 27.5 million Series B fundraising round

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.

1 Dec 2011

Joslin study uncovers potential targets for soft-tissue sarcomas

Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors.

30 Nov 2011

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center.

30 Nov 2011

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.

30 Nov 2011

DNA gyrase B could rapidly eliminate TB, shorten treatment time

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

30 Nov 2011

PTC, Roche announce licensing agreement for SMA programme

Roche, PTC Therapeutics, Inc. and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.

30 Nov 2011

BioLineRx reports third quarter net loss of NIS 7.9 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2011.

29 Nov 2011

Scientists use genetic methods to successfully repair cleft lips in mice embryos

Scientists at Weill Cornell Medical College used genetic methods to successfully repair cleft lips in mice embryos specially engineered for the study of cleft lip and cleft palate. The research breakthrough may show the way to prevent or treat the conditions in humans.

29 Nov 2011

GVK Biosciences and Moulder Center at Temple University enter drug discovery alliance

GVK Biosciences, Asia's leading drug discovery research & development organization, announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.

28 Nov 2011

Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A

Inspiration Biopharmaceuticals, Inc. today announced the initiation of patient enrollment in the second of two pivotal studies in the Company's OBI-1 Accur8 clinical trial program.

28 Nov 2011

MedImmune, U-M to work toward new biologic options for cancer and other diseases

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects.

22 Nov 2011

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

ChanRx is developing a superior drug for treatment of atrial fibrillation (AFIB), and has closed its Series A funding with investments from Sante Ventures and company founder, Dr. Arthur "Buzz" Brown. The company, a spin out of Cleveland-based ChanTest, will use the funding to further evaluate the safety and efficacy of its proprietary AFIB drug, vanoxerine.

21 Nov 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).

21 Nov 2011

Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SEL-068, a nicotine vaccine candidate for smoking cessation and relapse prevention.

21 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Gold nanoparticles help detect lung cancer in exhaled breath

The metabolism of lung cancer patients is different than the metabolism of healthy people. And so the molecules that make up cancer patients' exhaled breath are different too.

17 Nov 2011

Mirna reports new preclinical data of miRNA-based therapeutic candidate for hepatocellular carcinoma

Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA replacement therapy for cancer, announced the presentation today of new preclinical data on the development of a miRNA-based therapeutic candidate for primary liver cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.

16 Nov 2011

CDCs can increase healthy heart muscle cells in patients with ischemic heart disease

Healthy, new heart cells have been generated by animals with chronic ischemic heart disease after receiving stem cells derived from cardiac biopsies or "cardiospheres," according to research conducted at the University at Buffalo School of Medicine and Biomedical Sciences.

16 Nov 2011

Preclinical News and Research

Onconova uses BioClinica EDC, data management services to support clinical trials

arGEN-X closes EUR 27.5 million Series B fundraising round

Joslin study uncovers potential targets for soft-tissue sarcomas

Combination treatment improves progression-free survival in pancreatic neuroendocrine tumors

Neogenix novel antibody selected as one of Windhover's 2011 Top 10 Projects to Watch

DNA gyrase B could rapidly eliminate TB, shorten treatment time

PTC, Roche announce licensing agreement for SMA programme

BioLineRx reports third quarter net loss of NIS 7.9 million

Scientists use genetic methods to successfully repair cleft lips in mice embryos

GVK Biosciences and Moulder Center at Temple University enter drug discovery alliance

Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A

MedImmune, U-M to work toward new biologic options for cancer and other diseases

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Gold nanoparticles help detect lung cancer in exhaled breath

Mirna reports new preclinical data of miRNA-based therapeutic candidate for hepatocellular carcinoma

CDCs can increase healthy heart muscle cells in patients with ischemic heart disease

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics